{"id":"NCT01148017","sponsor":"Novartis Vaccines","briefTitle":"Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","officialTitle":"A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2010-06-22","resultsPosted":"2014-05-14","lastUpdate":"2017-08-14"},"enrollment":433,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine","otherNames":[]}],"arms":[{"label":"ACWY - 4","type":"EXPERIMENTAL"},{"label":"ACWY - 2","type":"EXPERIMENTAL"},{"label":"Naïve - 40","type":"OTHER"},{"label":"Naïve - 60","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective was to evaluate the persistence of bactericidal antibodies in children 40 and 60 months of age previously enrolled in the V59P14 (NCT00474526) study who received Novartis MenACWY Conjugate Vaccine. The study also enrolled age-matched subjects who have never received any meningococcal vaccine (naïve subjects) to serve as a control group. In addition, the response of a booster dose at 60 months was evaluated.","primaryOutcome":{"measure":"Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 1:8 Directed Against N. Meningitidis Serogroups A, C, W-135, and Y","timeFrame":"Visit 9 (continuation from the parent study), 40-month visit.","effectByArm":[{"arm":"ACWY - 4","deltaMin":10,"sd":null},{"arm":"ACWY - 2","deltaMin":35,"sd":null},{"arm":"Naïve - 40","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"37 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["31279564"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":132},"commonTop":["Injection site pain","Injection site erythema","Injection site induration","Irritability","Somnolence"]}}